Under construction – not a live service

Skip to content

Frontlight Research

Institution

Habib hospital Thameur

Tunis, TunisiaWebsite

3running trials
2,265publications (OpenAlex)

Running trials

Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390· Phase 3· Eli Lilly and Company· Source
Recruiting
CRUZ Tunisia-Multivessel Registry
NCT06663696· Sahajanand Medical Technologies Limited· Source
Active, not recruiting
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411· Phase 2/3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Chronic kidney disease1 recruiting
Coronary artery disease1 recruiting
Stroke1 recruiting

Registry name variants (2)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Hopital Habib Thameur
Tunis, 1008
2 trials
- NCT07241390A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
  Contact: Fatma Boussema (principal investigator)
- NCT03466411A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
Habib Thameur Hospital
Tunis, 1089
1 trial
- NCT06663696CRUZ Tunisia-Multivessel Registry
  Contact: Pr. Kraiem Sondess (sub-investigator)

Institution data: ROR 0393ghj09 (CC0-1.0)Updated 3 Nov 2026

Report an error